☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Merck
Merck Join Forces with Hansoh Pharma to Develop HS-10535
December 20, 2024
Merck Discontinues Clinical Development Programs Evaluating Vibostolimab and Favezelimab for Various Indications
December 19, 2024
Merck Reports the US FDA’s BLA Acceptance of Clesrovimab to Protect Infants from RSV Disease
December 18, 2024
China's NMPA Approves Merck’s Keytruda Plus Chemotherapy as Neoadjuvant Treatment of NSCLC
December 17, 2024
Merck Reports the CHMP’s Positive Opinion of Welireg (Belzutifan) for Von Hippel-Lindau (VHL) Disease-Associated Tumors and Previo...
December 16, 2024
Merck Reports the P-III (KEYLYNK-001) Study Data of Keytruda for Treating Advanced Epithelial Ovarian Cancer
December 10, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.